# Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

> **NCT02748304** · NA · TERMINATED · sponsor: **Fudan University** · enrollment: 52 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **OTHER:** control
- **DRUG:** sorafenib
- **DRUG:** aspirin

## Key facts

- **NCT ID:** NCT02748304
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2019-02-11
- **Final completion:** 2019-02-11
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02748304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02748304, "Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02748304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*